The Attenuated End of the Phenotypic Spectrum in MPS III: from Late-onset Stable Cognitive Impairment to a Non-neuronopathic Phenotype
Overview
Authors
Affiliations
Background: The phenotypic spectrum of many rare disorders is much wider than previously considered. Mucopolysaccharidosis type III (Sanfilippo syndrome, MPS III), is a lysosomal storage disorder traditionally considered to be characterized by childhood onset, progressive neurocognitive deterioration with a rapidly or slowly progressing phenotype. The presented MPS III case series demonstrates adult onset phenotypes with mild cognitive impairment or non-neuronopathic phenotypes.
Methods: In this case series all adult MPS III patients with a mild- or non-neuronopathic phenotype, who attend the outpatient clinic of 3 expert centers for lysosomal storage disorders were included. A mild- or non-neuronopathic phenotype was defined as having completed regular secondary education and attaining a level of independency during adulthood, involving either independent living or a paid job.
Results: Twelve patients from six families, with a median age at diagnosis of 43 years (range 3-68) were included (11 MPS IIIA, 1 MPS IIIB). In the four index patients symptoms which led to diagnostic studies (whole exome sequencing and metabolomics) resulting in the diagnosis of MPS III; two patients presented with retinal dystrophy, one with hypertrophic cardiomyopathy and one with neurocognitive decline. The other eight patients were diagnosed by family screening. At a median age of 47 years (range 19-74) 9 out of the 12 patients had normal cognitive functions. Nine patients had retinal dystrophy and 8 patients hypertrophic cardiomyopathy.
Conclusion: We show the very mild end of the phenotypic spectrum of MPS III, ranging from late-onset stable neurocognitive impairment to a fully non-neuronopathic phenotype. Awareness of this phenotype could lead to timely diagnosis and genetic counseling.
Szaraz D, Ksinan A, Machacek C, Borilova Linhartova P Orphanet J Rare Dis. 2025; 20(1):103.
PMID: 40038706 PMC: 11881262. DOI: 10.1186/s13023-025-03623-5.
Anikiej-Wiczenbach P, Limanowka M, Mazurkiewicz-Beldzinska M, Pierzynowska K, Wegrzyn G, Wierzba J J Appl Genet. 2024; .
PMID: 39739235 DOI: 10.1007/s13353-024-00934-4.
Mucopolysaccharidosis Type IIIE: A Real Human Disease or a Diagnostic Pitfall?.
Wisniewska K, Wolski J, Zabinska M, Szulc A, Gaffke L, Pierzynowska K Diagnostics (Basel). 2024; 14(16).
PMID: 39202222 PMC: 11353205. DOI: 10.3390/diagnostics14161734.
Warner-Levy J, Heald A, Hand D, Sharma R, Thomasson R, Stepien K Genes (Basel). 2024; 15(7).
PMID: 39062702 PMC: 11276493. DOI: 10.3390/genes15070923.
Lin S, Robson A, Thompson D, Stepien K, Lachmann R, Footitt E Clin Genet. 2024; 106(4):505-511.
PMID: 38863195 PMC: 7616411. DOI: 10.1111/cge.14573.